TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00445341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavopiridol
Description: Flavopiridol 30 mg/m\^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
Study: NCT01203124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
Study: NCT00143637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clean air
Description: Clean air
Study: NCT04589806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2-stage ridge splitting
Description: two-stage alveolar ridge splitting technique using piezoelectric device with simultaneous implant placement in order to treat narrow posterior mandibular ridges avoiding the risks of malfracture and necrosis of the split part
Study: NCT01073033

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk supplement 1
Description: milk supplement with probiotics
Study: NCT01203124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01073033

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: milk supplement 2
Description: milk supplement without probiotics
Study: NCT02140086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buteyko based Remedial Breathing Therapy
Description: Buteyko based remedial Breathing Therapy after Dr. Buteyko
Study: NCT01203124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03093883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrinemia
Description: Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venofer
Description: Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Study: NCT01201850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin®)
Description: Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
Study: NCT01600469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOI-B
Description: 250-1500 mg/day, oral, for 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, oral, for 24 weeks
Study: NCT03442205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LC + LCBDE + ENBD + primary closure of CBD
Description: LC + LCBDE + ENBD + primary closure of CBD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP technique + LC
Description: ERCP technique + LC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LC + LCBDE + primary closure of CBD
Description: LC + LCBDE + primary closure of CBD
Study: NCT01616069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine and levosimendan
Description: epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine and levosimendan
Description: epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
Study: NCT01156363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis
Description: regular haemodialysis or peritoneal dialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: once monthly, subcutaneously or intravenously, for 32 weeks
Study: NCT04880993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg tablets
Description: Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Farxiga® 10 mg tablets
Description: Manufactured by AstraZeneca Pharmaceuticals LP
Study: NCT00985738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
Study: NCT02262338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-182
Description: Recombinant HIRMAb-IDS
Study: NCT00981682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120
Description: once a day treatment of nocturia
Study: NCT02617329

Intervention type: OTHER
Group type: OTHER
Intervention: Extracorporeal shock wave therapy (ESWT)
Description: The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group

Intervention type: OTHER
Group type: OTHER
Intervention: cervical flexion
Description: Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
Study: NCT02945306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Watchful waiting with supportive care
Description: Use of widely prescribed medicines to treat associated conditions
Study: NCT00004604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA RNA-pulsed DC cancer vaccine
Description: carcinoembryonic antigen RNA-pulsed dendritic cells
Study: NCT03152396

Intervention type: OTHER
Group type: OTHER
Intervention: CV risk assessment and modification of global risk
Description: Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.
Study: NCT02303366

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiosurgery (SABR)
Description: Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
Study: NCT03733899

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Minims Proxymetacaine hydrochloride Eye Drops

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Minims Proxymetacaine hydrochloride Eye Drops

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Minims Proxymetacaine hydrochloride Eye Drops

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Minims Proxymetacaine hydrochloride Eye Drops

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Minims Proxymetacaine hydrochloride Eye Drops

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Minims Proxymetacaine hydrochloride Eye Drops
Study: NCT01318993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786A
Description: 500 milligrams twice daily
Study: NCT00864331

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: 39 Gy in 13 daily fractions of 3 Gy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy
Description: Chemotherapy followed by low dose palliative radiotherapy
Study: NCT03733899

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride Solution

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride Solution

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride Solution

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride Solution

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride Solution

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride Solution
Study: NCT00864331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy given alone
Study: NCT03136900

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrilon without lactose® fortified by concentration
Description: enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
Study: NCT02390687

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Study: NCT03136900

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrilon without lactose® fortified by Maltodextrin and oil supplementation
Description: enteral diet with cow milk protein-based infant formula without lactose 14%
Study: NCT03191812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
Study: NCT04379947

Intervention type: PROCEDURE
Intervention: Fractional Flow reserve
Description: Measurement of fractional flow reserve in the preoperative work-up for oronary artery bypass surgery
Study: NCT00608842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Administered via intralipomal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Administered via intralipomal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Administered via intralipomal injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching vehicle placebo administered via intralipomal injection.
Study: NCT04583969

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lenzilumab
Description: Lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human GM-CSF, with potential immunomodulating activity, high binding affinity in the pM range, and 94% specificity to the human germline, which reduces immunogenicity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for lenzilumab is commercially sourced 0.9% sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
Study: NCT00971360

Intervention type: OTHER
Intervention: conversion disorder
Description: Proinflammatory cytokine levels in conversion disorder

Intervention type: OTHER
Intervention: conversion disorder
Description: Proinflammatory cytokine levels in conversion disorder
Study: NCT00864331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy and chemotherapy
Description: Low dose palliative radiotherapy followed by chemotherapy
Study: NCT00356291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skill-Building (SB) plus Motivational Interviewing
Description: SB is a 4 to 5 session individually-based psychoeducational intervention. Participants meet weekly with an interventionist for 3 to 4 weeks and then receive a booster session 3 months after baseline. The traditional Skill-Building intervention will be augmented with Motivational Interviewing techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skill-Building (SB)
Description: SB is a 4-session individually-based psychoeducational HIV risk reduction intervention. Participants meet weekly with an interventionist for 3 weeks and then receive a booster session 3 months after baseline.
Study: NCT02548780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
Study: NCT03689972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg IV infusion.
Study: NCT04014816

Intervention type: OTHER
Intervention: MDR bacteria positivity
Description: A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.

Intervention type: OTHER
Intervention: MDR bacteria positivity
Description: A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.

Intervention type: OTHER
Intervention: negative fluid balance
Description: A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.

Intervention type: OTHER
Intervention: negative fluid balance
Description: A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
Study: NCT00433121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertralin
Study: NCT03902288

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh pomegranate juice
Description: Pomegranate seeds (arils) were separated by hand, and fresh pomegranate juice was prepared by squeezing the seeds using a fruit squeezing machine. Fresh pomegranate juice was given at 1.5 mL/kg of body weight for the fasted recruited patient with type 2 diabetes (FSG \< 15.8 mmol/L). Blood was collected before and after 1 and 3 hours of ingesting the juice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh pomegranate juice
Description: Pomegranate seeds (arils) were separated by hand, and fresh pomegranate juice was prepared by squeezing the seeds using a fruit squeezing machine. Fresh pomegranate juice was given at 1.5 mL/kg of body weight for the fasted recruited patient with type 2 diabetes (FSG \< 15.8 mmol/L). Blood was collected before and after 1 and 3 hours of ingesting the juice.
Study: NCT06116760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal or sham tDCS
Description: Anodal or sham tDCS (see Arms) is applied during the execution of an audio-visual training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal or sham tDCS
Description: Anodal or sham tDCS (see Arms) is applied during the execution of an audio-visual training.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Anodal or sham tDCS
Description: Anodal or sham tDCS (see Arms) is applied during the execution of an audio-visual training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio-visual training
Description: 90 min/day x 10 days. Participants are seated in front of a 2 m × 2 m training board, at a distance of 1.2 m, in a dimly lit room. The board features 48 red light-emitting diodes (LED, diameter 1 cm, luminance 90 cd m2), distributed in six horizontal rows (eight lights per row). Forty-eight piezoelectric loudspeakers (0.4 W, 8Ω) are located above each light, producing a white-noise (80 dB, duration 100 ms).~Spatio-temporally congruent, cross-modal, audio-visual stimuli are presented at one out of 48 possible positions on the board. Participants are instructed to look at the fixation point - at the center of the apparatus - and to move their eyes to detect the presence of the visual stimulus (duration=100 ms) by pressing right button of a wireless mouse.
Study: NCT03689972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg SC injection or IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg SC injection or IV infusion.
Study: NCT02068950

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Progressive resistance training
Description: A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
Study: NCT04128605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB)
Description: SSNB is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. Then, a mixture of 5 mls of Bupivacaine, 5 mls Lidocaine 1% and 10 mls of saline are injected at posterior shoulder towards suprascapular notch surrounding suprascapular nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular shoulder steroid injection (IAS)
Description: IAS is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. IAS is performed by injecting 40 mg of Triamcenolone Acetonide along with 2 ml of Lidocaine 1% into glenohumeral articular space
Study: NCT01318525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALF-5755
Description: 10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution (0.9% NaCl)
Description: 25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe